Reuters logo
13 天前
BRIEF-Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​
2017年8月10日 / 晚上8点40分 / 13 天前

BRIEF-Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​

Aug 10 (Reuters) - Crispr Therapeutics Ag

* Crispr Therapeutics announces second quarter 2017 financial results and provides business update

* Crispr Therapeutics Ag - ‍as of June 30, 2017, Crispr Therapeutics had $272.3 million in cash as compared to $315.5 million in cash as of December 31, 2016​

* Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​

* Crispr Therapeutics Ag - ‍lead hemoglobinopathies program remains on track to file CTA by year-end 2017, and begin clinical trials in 2018​

* Crispr Therapeutics Ag - ‍remains on track to file a clinical trial application (CTA) in Europe by year-end 2017 for beta-thalassemia​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below